Search

Your search keyword '"Angel Alonso‐Gómez"' showing total 7 results
Start Over Author "Angel Alonso‐Gómez"
7 results on '"Angel Alonso‐Gómez"'

1. Lysine pathway metabolites and the risk of type 2 diabetes and cardiovascular disease in the PREDIMED study: results from two case-cohort studies

Author

Cristina Razquin, Miguel Ruiz-Canela, Clary B. Clish, Jun Li, Estefania Toledo, Courtney Dennis, Liming Liang, Albert Salas-Huetos, Kerry A. Pierce, Marta Guasch-Ferré, Dolores Corella, Emilio Ros, Ramon Estruch, Enrique Gómez-Gracia, Montse Fitó, Jose Lapetra, Dora Romaguera, Angel Alonso-Gómez, Lluis Serra-Majem, Jordi Salas-Salvadó, Frank B. Hu, and Miguel A. Martínez-González

Subjects
Biomarkers, Metabolites, Cardiovascular disease, Type 2 diabetes, Dietary intervention, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Abstract Background The pandemic of cardiovascular disease (CVD) and type 2 diabetes (T2D) requires the identification of new predictor biomarkers. Biomarkers potentially modifiable with lifestyle changes deserve a special interest. Our aims were to analyze: (a) The associations of lysine, 2-aminoadipic acid (2-AAA) or pipecolic acid with the risk of T2D or CVD in the PREDIMED trial; (b) the effect of the dietary intervention on 1-year changes in these metabolites, and (c) whether the Mediterranean diet (MedDiet) interventions can modify the effects of these metabolites on CVD or T2D risk. Methods Two unstratified case-cohort studies nested within the PREDIMED trial were used. For CVD analyses, we selected 696 non-cases and 221 incident CVD cases; for T2D, we included 610 non-cases and 243 type 2 diabetes incident cases. Metabolites were quantified using liquid chromatography–tandem mass spectrometry, at baseline and after 1-year of intervention. Results In weighted Cox regression models, we found that baseline lysine (HR+1 SD increase = 1.26; 95% CI 1.06–1.51) and 2-AAA (HR+1 SD increase = 1.28; 95% CI 1.05–1.55) were both associated with a higher risk of T2D, but not with CVD. A significant interaction (p = 0.032) between baseline lysine and T2D on the risk of CVD was observed: subjects with prevalent T2D and high levels of lysine exhibited the highest risk of CVD. The intervention with MedDiet did not have a significant effect on 1-year changes of the metabolites. Conclusions Our results provide an independent prospective replication of the association of 2-AAA with future risk of T2D. We show an association of lysine with subsequent CVD risk, which is apparently diabetes-dependent. No evidence of effects of MedDiet intervention on lysine, 2-AAA or pipecolic acid changes was found. Trial registration ISRCTN35739639; registration date: 05/10/2005; recruitment start date 01/10/2003

Published
2019
Full Text
View/download PDF

2. Persistent Pulmonary Hypertension in Corrected Valvular Heart Disease: Hemodynamic Insights and Long‐Term Survival

Author

Javier Bermejo, Ana González‐Mansilla, Teresa Mombiela, Ana I. Fernández, Pablo Martínez‐Legazpi, Raquel Yotti, Rocío García‐Orta, Pedro L. Sánchez‐Fernández, Mario Castaño, Javier Segovia‐Cubero, Pilar Escribano‐Subias, J. Alberto San Román, Xavier Borrás, Angel Alonso‐Gómez, Javier Botas, María G. Crespo‐Leiro, Sonia Velasco, Antoni Bayés‐Genís, Amador López, Roberto Muñoz‐Aguilera, Manuel Jiménez‐Navarro, José R. González‐Juanatey, Arturo Evangelista, Jaime Elízaga, Javier Martín‐Moreiras, José M. González‐Santos, Eduardo Moreno‐Escobar, and Francisco Fernández‐Avilés

Subjects
heart failure, pulmonary hypertension, valvular heart disease, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Background The determinants and consequences of pulmonary hypertension after successfully corrected valvular heart disease remain poorly understood. We aim to clarify the hemodynamic bases and risk factors for mortality in patients with this condition. Methods and Results We analyzed long‐term follow‐up data of 222 patients with pulmonary hypertension and valvular heart disease successfully corrected at least 1 year before enrollment who had undergone comprehensive hemodynamic and imaging characterization as per the SIOVAC (Sildenafil for Improving Outcomes After Valvular Correction) clinical trial. Median (interquartile range) mean pulmonary pressure was 37 mm Hg (32–44 mm Hg) and pulmonary artery wedge pressure was 23 mm Hg (18–26 mm Hg). Most patients were classified either as having combined precapillary and postcapillary or isolated postcapillary pulmonary hypertension. After a median follow‐up of 4.5 years, 91 deaths accounted for 4.21 higher‐than‐expected mortality in the age‐matched population. Risk factors for mortality were male sex, older age, diabetes mellitus, World Health Organization functional class III and higher pulmonary vascular resistance—either measured by catheterization or approximated from ultrasound data. Higher pulmonary vascular resistance was related to diabetes mellitus and smaller residual aortic and mitral valve areas. In turn, the latter correlated with prosthetic nominal size. Six‐month changes in the composite clinical score and in the 6‐minute walk test distance were related to survival. Conclusions Persistent valvular heart disease–pulmonary hypertension is an ominous disease that is almost universally associated with elevated pulmonary artery wedge pressure. Pulmonary vascular resistance is a major determinant of mortality in this condition and is related to diabetes mellitus and the residual effective area of the corrected valve. These findings have important implications for individualizing valve correction procedures. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT00862043.

Published
2021
Full Text
View/download PDF

3. Circulating Amino Acids and Risk of Peripheral Artery Disease in the PREDIMED Trial

Author

Cristina Razquin, Miguel Ruiz-Canela, Estefania Toledo, Clary B. Clish, Marta Guasch-Ferré, Jesús F. García-Gavilán, Clemens Wittenbecher, Angel Alonso-Gómez, Montse Fitó, Liming Liang, Dolores Corella, Enrique Gómez-Gracia, Ramon Estruch, Miquel Fiol, Jose M. Santos-Lozano, Luis Serra-Majem, Emilio Ros, Fernando Aros, Jordi Salas-Salvadó, Frank B. Hu, Miguel A. Martínez-González, [Razquin, Cristina] Univ Navarra, Dept Prevent Med & Publ Hlth, IdiSNA Inst Invest Sanitaria Navarra, Pamplona 31008, Spain, [Ruiz-Canela, Miguel] Univ Navarra, Dept Prevent Med & Publ Hlth, IdiSNA Inst Invest Sanitaria Navarra, Pamplona 31008, Spain, [Toledo, Estefania] Univ Navarra, Dept Prevent Med & Publ Hlth, IdiSNA Inst Invest Sanitaria Navarra, Pamplona 31008, Spain, [Martinez-Gonzalez, Miguel A.] Univ Navarra, Dept Prevent Med & Publ Hlth, IdiSNA Inst Invest Sanitaria Navarra, Pamplona 31008, Spain, [Razquin, Cristina] Inst Salud Carlos III, CIBER Fisiopatol Obes & Nutr CIBERObn, Madrid 28029, Spain, [Ruiz-Canela, Miguel] Inst Salud Carlos III, CIBER Fisiopatol Obes & Nutr CIBERObn, Madrid 28029, Spain, [Toledo, Estefania] Inst Salud Carlos III, CIBER Fisiopatol Obes & Nutr CIBERObn, Madrid 28029, Spain, [Garcia-Gavilan, Jesus F.] Inst Salud Carlos III, CIBER Fisiopatol Obes & Nutr CIBERObn, Madrid 28029, Spain, [Alonso-Gomez, Angel] Inst Salud Carlos III, CIBER Fisiopatol Obes & Nutr CIBERObn, Madrid 28029, Spain, [Fito, Montse] Inst Salud Carlos III, CIBER Fisiopatol Obes & Nutr CIBERObn, Madrid 28029, Spain, [Corella, Dolores] Inst Salud Carlos III, CIBER Fisiopatol Obes & Nutr CIBERObn, Madrid 28029, Spain, [Estruch, Ramon] Inst Salud Carlos III, CIBER Fisiopatol Obes & Nutr CIBERObn, Madrid 28029, Spain, [Fiol, Miquel] Inst Salud Carlos III, CIBER Fisiopatol Obes & Nutr CIBERObn, Madrid 28029, Spain, [Santos-Lozano, Jose M.] Inst Salud Carlos III, CIBER Fisiopatol Obes & Nutr CIBERObn, Madrid 28029, Spain, [Serra-Majem, Luis] Inst Salud Carlos III, CIBER Fisiopatol Obes & Nutr CIBERObn, Madrid 28029, Spain, [Ros, Emilio] Inst Salud Carlos III, CIBER Fisiopatol Obes & Nutr CIBERObn, Madrid 28029, Spain, [Aros, Fernando] Inst Salud Carlos III, CIBER Fisiopatol Obes & Nutr CIBERObn, Madrid 28029, Spain, [Salas-Salvado, Jordi] Inst Salud Carlos III, CIBER Fisiopatol Obes & Nutr CIBERObn, Madrid 28029, Spain, [Martinez-Gonzalez, Miguel A.] Inst Salud Carlos III, CIBER Fisiopatol Obes & Nutr CIBERObn, Madrid 28029, Spain, [Clish, Clary B.] Harvard Univ, Broad Inst MIT, Cambridge, MA 02142 USA, [Guasch-Ferre, Marta] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA, [Wittenbecher, Clemens] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA, [Hu, Frank B.] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA, [Martinez-Gonzalez, Miguel A.] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA, [Guasch-Ferre, Marta] Univ Copenhagen, Dept Publ Hlth, Sect Epidemiol, DK-1165 Copenhagen, Denmark, [Guasch-Ferre, Marta] Univ Copenhagen, Novo Nord Fdn Ctr Basic Metab Res, DK-1353 Copenhagen, Denmark, [Garcia-Gavilan, Jesus F.] Univ Rovira i Virgili, Dept Bioquim & Biotecnol, Unitat Nutr Humana, Reus 43201, Spain, [Salas-Salvado, Jordi] Univ Rovira i Virgili, Dept Bioquim & Biotecnol, Unitat Nutr Humana, Reus 43201, Spain, [Garcia-Gavilan, Jesus F.] Hosp Univ San Joan Reus, Inst Invest Sanitaria Pere Virgili IISPV, Reus 43204, Spain, [Salas-Salvado, Jordi] Hosp Univ San Joan Reus, Inst Invest Sanitaria Pere Virgili IISPV, Reus 43204, Spain, [Wittenbecher, Clemens] Chalmers Univ Technol, Dept Biol & Biol Engn, Food & Nutr Sci Div, SciLifeLab, SE-41296 Gothenburg, Sweden, [Alonso-Gomez, Angel] Univ Basque Country UPV EHU, Araba Univ Hosp, Bioaraba Hlth Res Inst, Osakidetza Basque Hlth Serv, Vitoria 01009, Spain, [Aros, Fernando] Univ Basque Country UPV EHU, Araba Univ Hosp, Bioaraba Hlth Res Inst, Osakidetza Basque Hlth Serv, Vitoria 01009, Spain, [Fito, Montse] Inst Hosp del Mar Invest Med IMIM, Unit Cardiovasc Risk & Nutr, Barcelona 08003, Spain, [Liang, Liming] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol & Biostat, Boston, MA 02115 USA, [Corella, Dolores] Univ Valencia, Dept Prevent Med, Valencia 46100, Spain, [Gomez-Gracia, Enrique] Univ Malaga, Dept Prevent Med, Malaga 29071, Spain, [Estruch, Ramon] Univ Barcelona, Hosp Clin, Inst Invest Biomed August Pi Sunyer IDIBAPS, Dept Internal Med, Barcelona 08036, Spain, [Fiol, Miquel] Hosp Univ Son Espases, Plataforma Ensayos Clin, Inst Invest Sanitaria Illes Balears IdISBa, Palma De Mallorca 07120, Spain, [Santos-Lozano, Jose M.] Dist Sanitario Atenc Primaria Sevilla, Dept Family Med, Res Unit, Seville 41013, Spain, [Serra-Majem, Luis] Univ Las Palmas Gran Canaria, Res Inst Biomed & Hlth Sci IUIBS, Nutr Res Grp, Las Palmas Gran Canaria 35016, Spain, [Ros, Emilio] Univ Barcelona, Hosp Clin, Agust Pi Sunyer Biomed Res Inst IDIBAPS i, Dept Endocrinol & Nutr,Lipid Clin, Barcelona 08036, Spain, and [Hu, Frank B.] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA

Subjects
PREDIMED, amino acids, Predictors, Organic Chemistry, General Medicine, case-cohort, peripheral artery disease, metabolomics, Catalysis, Computer Science Applications, Association, Inorganic Chemistry, Life, Health, Physical and Theoretical Chemistry, Ratio, Molecular Biology, Spectroscopy
Abstract

Effective prevention and risk prediction are important for peripheral artery disease (PAD) due to its poor prognosis and the huge disease burden it produces. Circulating amino acids (AA) and their metabolites may serve as biomarkers of PAD risk, but they have been scarcely investigated. The objective was to prospectively analyze the associations of baseline levels of plasma AA (and their pathways) with subsequent risk of PAD and the potential effect modification by a nutritional intervention with the Mediterranean diet (MedDiet). A matched case-control study was nested in the PREDIMED trial, in which participants were randomized to three arms: MedDiet with tree nut supplementation group, MedDiet with extra-virgin olive oil (EVOO) supplementation group or control group (low-fat diet). One hundred and sixty-seven PAD cases were matched with 250 controls. Plasma AA was measured with liquid chromatography/mass spectrometry at the Broad Institute. Baseline tryptophan, serine and threonine were inversely associated with PAD (ORfor 1 SD increase = 0.78 (0.61–0.99); 0.67 (0.51–0.86) and 0.75 (0.59–0.95), respectively) in a multivariable-adjusted conditional logistic regression model. The kynurenine/tryptophan ratio was directly associated with PAD (ORfor 1 SD increase = 1.50 (1.14–1.98)). The nutritional intervention with the MedDiet+nuts modified the association between threonine and PAD (p-value interaction = 0.018) compared with the control group. However, subjects allocated to the MedDiet+EVOO group were protected against PAD independently of baseline threonine. Plasma tryptophan, kynurenine/tryptophan ratio, serine and threonine might serve as early biomarkers of future PAD in subjects at a high risk of cardiovascular disease. The MedDiet supplemented with EVOO exerted a protective effect, regardless of baseline levels of threonine.

Published
2022
Full Text
View/download PDF

4. Validation of Echocardiographic Measurements in Patients with Pulmonary Embolism in the RIETE Registry

Author

Mads Dam Lyhne, Behnood Bikdeli, David M. Dudzinski, Alfonso Muriel-García, Christopher Kabrhel, Teresa Sancho-Bueso, Esther Pérez-David, José Luis Lobo, Ángel Alonso-Gómez, David Jiménez, Manuel Monreal, and the RIETE Investigators

Subjects
echocardiography, right ventricular function, validity, pulmonary circulation, reliability, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Background In acute pulmonary embolism (PE), echocardiographic identification of right ventricular (RV) dysfunction will inform prognostication and clinical decision-making. Registro Informatizado Enfermedad TromboEmbolica (RIETE) is the world's largest registry of patients with objectively confirmed PE. The reliability of site-reported RV echocardiographic measurements is unknown. We aimed to validate site-reported key RV echocardiographic measurements in the RIETE registry.

Published
2024
Full Text
View/download PDF

5. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial

Author

Javier, Bermejo, Raquel, Yotti, Rocío, García-Orta, Pedro L, Sánchez-Fernández, Mario, Castaño, Javier, Segovia-Cubero, Pilar, Escribano-Subías, José Alberto, San Román, Xavier, Borrás, Angel, Alonso-Gómez, Javier, Botas, María G, Crespo-Leiro, Sonia, Velasco, Antoni, Bayés-Genís, Amador, López, Roberto, Muñoz-Aguilera, Eduardo, de Teresa, José R, González-Juanatey, Arturo, Evangelista, Teresa, Mombiela, Ana, González-Mansilla, Jaime, Elízaga, Javier, Martín-Moreiras, José M, González-Santos, Eduardo, Moreno-Escobar, Francisco, Fernández-Avilés, and Joaquín, Alonso

Subjects
Male, medicine.medical_specialty, Heart Diseases, Sildenafil, Hypertension, Pulmonary, Vasodilator Agents, MEDLINE, Heart Valve Diseases, Fast Track Clinical Research, 030204 cardiovascular system & hematology, Sildenafil Citrate, Pulmonary hypertension, law.invention, Double blind, Placebos, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Randomized controlled trial, Double-Blind Method, law, Internal medicine, medicine, Humans, In patient, 030212 general & internal medicine, Pulmonary Wedge Pressure, Aged, Heart Failure, business.industry, Persistent pulmonary hypertension, valvular heart disease, medicine.disease, Valvular heart disease, respiratory tract diseases, Editor's Choice, Treatment Outcome, chemistry, Multicenter study, Valvular Heart Disease, cardiovascular system, Fast Track, Female, Cardiology and Cardiovascular Medicine, business
Abstract

Aims We aimed to determine whether treatment with sildenafil improves outcomes of patients with persistent pulmonary hypertension (PH) after correction of valvular heart disease (VHD). Methods and results The sildenafil for improving outcomes after valvular correction (SIOVAC) study was a multricentric, randomized, parallel, and placebo-controlled trial that enrolled stable adults with mean pulmonary artery pressure ≥ 30 mmHg who had undergone a successful valve replacement or repair procedure at least 1 year before inclusion. We assigned 200 patients to receive sildenafil (40 mg three times daily, n = 104) or placebo (n = 96) for 6 months. The primary endpoint was the composite clinical score combining death, hospital admission for heart failure (HF), change in functional class, and patient global self-assessment. Only 27 patients receiving sildenafil improved their composite clinical score, as compared with 44 patients receiving placebo; in contrast 33 patients in the sildenafil group worsened their composite score, as compared with 14 in the placebo group [odds ratio 0.39; 95% confidence interval (CI) 0.22–0.67; P

Published
2017

6. Mediterranean diet and risk of heart failure: results from the PREDIMED randomized controlled trial

Author

Angeliki, Papadaki, Miguel Ángel, Martínez-González, Angel, Alonso-Gómez, Javier, Rekondo, Jordi, Salas-Salvadó, Dolores, Corella, Emilio, Ros, Montse, Fitó, Ramon, Estruch, José, Lapetra, Antonio, García-Rodriguez, Miquel, Fiol, Lluís, Serra-Majem, Xavier, Pintó, Miguel, Ruiz-Canela, Monica, Bulló, Mercè, Serra-Mir, Jose V, Sorlí, and Fernando, Arós

Subjects
Heart Failure, Male, Incidence, Statistics as Topic, Middle Aged, Diet, Mediterranean, Risk Assessment, Outcome and Process Assessment, Health Care, Cardiovascular Diseases, Dietary Supplements, Humans, Nuts, Female, Olive Oil, Aged
Abstract

The aim of this study was to evaluate the effect of the Mediterranean diet (MedDiet) on the incidence of heart failure (HF), a pre-specified secondary outcome in the PREDIMED (PREvención con DIeta MEDiterránea) primary nutrition-intervention prevention trial.Participants at high risk of cardiovascular disease were randomly assigned to one of three diets: MedDiet supplemented with extra-virgin olive oil (EVOO), MedDiet supplemented with nuts, or a low-fat control diet. Incident HF was ascertained by a Committee for Adjudication of events blinded to group allocation. Among 7403 participants without prevalent HF followed for a median of 4.8 years, we observed 29 new HF cases in the MedDiet with EVOO group, 33 in the MedDiet with nuts group, and 32 in the control group. No significant association with HF incidence was found for the MedDiet with EVOO and MedDiet with nuts, compared with the control group [hazard ratio (HR) 0.68; 95% confidence interval (CI) 0.41-1.13, and HR 0.92; 95% CI 0.56-1.49, respectively].In this sample of adults at high cardiovascular risk, the MedDiet did not result in lower HF incidence. However, this pre-specified secondary analysis may have been underpowered to provide valid conclusions. Further randomized controlled trials with HF as a primary outcome are needed to better assess the effect of the MedDiet on HF risk.ISRCTN35739639.

Published
2016

7. Type 2 diabetes and cognitive impairment in an older population with overweight or obesity and metabolic syndrome: baseline cross-sectional analysis of the PREDIMED-plus study

Author

Núria Mallorquí-Bagué, María Lozano-Madrid, Estefanía Toledo, Dolores Corella, Jordi Salas-Salvadó, Aida Cuenca-Royo, Jesús Vioque, Dora Romaguera, J. Alfredo Martínez, Julia Wärnberg, José López-Miranda, Ramón Estruch, Aurora Bueno-Cavanillas, Ángel Alonso-Gómez, Josep A. Tur, Francisco J. Tinahones, Lluís Serra-Majem, Vicente Martín, José Lapetra, Clotilde Vázquez, Xavier Pintó, Josep Vidal, Lidia Daimiel, José J. Gaforio, Pilar Matía, Emilio Ros, Roser Granero, Pilar Buil-Cosiales, Rocío Barragán, Mònica Bulló, Olga Castañer, Manoli García-de-la-Hera, Aina M. Yáñez, Itziar Abete, Antonio García-Ríos, Miguel Ruiz-Canela, Andrés Díaz-López, Susana Jiménez-Murcia, Miguel A. Martínez-González, Rafael De la Torre, and Fernando Fernández-Aranda

Subjects
Baseline Cross-sectional Analysis, Glycaemic Control, Diabetes Treatment Adherence, Apnoea, Cognitive Function Performance, Medicine, Science
Abstract

Abstract This study cross-sectionally examines in the elderly population: (a) the association of type 2 diabetes with executive function (EF); (b) the effect of BMI on both type 2 diabetes and EF; (c) the association between glycaemia control and EF in type 2 diabetes. 6823 older individuals with overweight/obesity and metabolic syndrome participating in the PREDIMED-PLUS study, were assessed with a battery of cognitive tests and a medical interview. ANOVA showed a significantly worse performance on EF in type 2 diabetes vs. non-diabetic individuals. Two complementary models were displayed: (1) in the whole sample, the presence of type 2 diabetes, depressive symptoms and BMI had a direct negative effect on EF, while apnoea had an indirect negative effect; (2) in the diabetes subsample, higher illness duration was associated with worse performance in EF. Participants with type 2 diabetes and HbA1c

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results